2. NF-κB Immunology/Inflammation Metabolic Enzyme/Protease
  3. NF-κB Ser/Thr Protease Toll-like Receptor (TLR)
  4. Evolocumab

Evolocumab  (Synonyms: AMG 145)

製品番号: HY-P9930 純度: 98.4%
COA Technical Support

Evolocumab (AMG 145) is a human monoclonal antibody that inhibits PCSK9. Evolocumab is used in the study of hypercholesterolemia and atherosclerotic cardiovascular disease. Evolocumab binds to circulating PCSK9 protein and inhibits its binding to LDLR. Evolocumab has antioxidant and cytoprotective activities against H2O2-induced oxidative damage to endothelial cells. Evolocumab may also negatively regulate activation of the TLR-4/NF-κB signaling pathway to prevent inflammation.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号 : 1256937-27-5

容量 価格（税別） 在庫状況 数量
1 mg $280 在庫あり
5 mg $950 在庫あり
10 mg $1500 在庫あり
25 mg $2400 在庫あり
50 mg $3600 在庫あり
100 mg   お問い合わせ  
200 mg   お問い合わせ  

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 3 publication(s) in Google Scholar

Evolocumab Featured Recommendations:

Evolocumab 関連抗体

Top Publications Citing Use of Products

    Evolocumab purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2024 Feb:220:115996.  [Abstract]

    There was no difference in the 24-hour myocardial infarct size between the Evolocumab (subcutaneously injected, 30 mg/kg, 30 min before operation) treatment group and the myocardial infarction (MI) group.

    Evolocumab purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2024 Feb:220:115996.  [Abstract]

    The degree of myocardial fibrosis in the MI + evolocumab (subcutaneously injected, 30 mg/kg, 30 min before operation) group was lower than that in the MI + vehicle (Veh) group.

    Evolocumab purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2024 Feb:220:115996.  [Abstract]

    Evolocumab (subcutaneously injected, 30 mg/kg, 30 min before operation) decreased the collagen I, collagen III, and α-SMA proteins induced by the myocardial infarction (MI) model in rats.

    Evolocumab purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2024 Feb:220:115996.  [Abstract]

    WGA staining showed that evolocumab (subcutaneously injected, 30 mg/kg, 30 min before operation) treatment could reduce cardiomyocyte volume after myocardial infarction in a rat MI model.

    Evolocumab purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2024 Feb:220:115996.  [Abstract]

    Evolocumab (subcutaneously injected, 30 mg/kg, 30 min before operation) treatment improved cardiac function after myocardial infarction in myocardial infarction model rats.

    NF-κB アイソフォーム固有の製品をすべて表示:

    すべてのアイソフォームを表示
    NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

    Toll-like Receptor (TLR) アイソフォーム固有の製品をすべて表示:

    すべてのアイソフォームを表示
    TLR3 TLR8 TLR9 TLR2 TLR4 TLR7 TLR1 TLR6

    • 生物活性

    • 純度とドキュメンテーション

    • 参考文献

    • カスタマーレビュー

    製品説明

    Evolocumab (AMG 145) is a human monoclonal antibody that inhibits PCSK9. Evolocumab is used in the study of hypercholesterolemia and atherosclerotic cardiovascular disease. Evolocumab binds to circulating PCSK9 protein and inhibits its binding to LDLR. Evolocumab has antioxidant and cytoprotective activities against H2O2-induced oxidative damage to endothelial cells. Evolocumab may also negatively regulate activation of the TLR-4/NF-κB signaling pathway to prevent inflammation[1][2][3].

    Isotype

    Human IgG2 lambda
    Recommend Isotype Controls
    Species Reactivity

    Human
    IC50 & Target

    PCSK9
    体外実験

    Evolocumab (5-100 μg/mL) can significantly prevent the cytotoxicity of H2O2 on human umbilical vein endothelial cells (HUVEC)[2].
    Evolocumab (100 μg/mL) can reduce the expression and secretion of inflammatory factors increased by stimulation of rat retinal Müller cells (RMC)[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Evolocumab 関連抗体
    臨床実験
    Gene ID

    255738  [NCBI]

    Accession
    Application

    ELISA, FACS, Functional assay
    Conjugated

    Unconjugated
    Reconsititution

    The product can be reconstituted/diluted with sterile PBS or saline.
    分子量

    141.8 kDa

    CAS 番号
    Appearance

    Liquid

    Color

    Colorless to light yellow

    SMILES

    [Evolocumab]
    Formulation

    Please refer to the lot-specific COA for specific buffer information.
    保管条件

    Please store the product under the recommended conditions in the Certificate of Analysis.
    Format
    • Human IgG2 lambda
    Biological Activity
    • Immobilized PCSK9 Protein, Human can bind Evolocumab. The EC50 for this effect is 574 ng/mL.
    • Flow Cytometry analysis of Hela cells labelling PCSK9 (red) with Evolocumab (anti-PCSK9) (HY-P9930). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG2 lambda (HY-P991206). Black-Unlabelled control, cells without incubation with primary antibody.
    純度とドキュメンテーション

    純度: 98.40%

    COA (232 KB)

    Inhibitory Antibodies User Guide (603 KB)
    参考文献
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Evolocumab Related Classifications

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質量   濃度   体積   分子量 *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    一般には略語で表示されます：C1V1 = C2V2

    濃度 （開始） × 体積 （開始） = 濃度 （終了） × 体積 （終了）
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Evolocumab1256937-27-5AMG 145AMG145AMG-145NF-κBSer/Thr ProteaseToll-like Receptor (TLR)Nuclear factor-κBNuclear factor-kappaBSerine proteasesSerine endopeptidasesThreonine proteasesPCSK9LDLRhypercholesterolemiaatherosclerotic cardiovascular diseaseInhibitorinhibitorinhibit

    最近チェックした製品:

    オンラインお問い合わせ

    Your information is safe with us. * Required Fields.

    製品名

    		  

    カスタマ需要量 *

    お名前 *

    		 

    タイトル

    メールアドレス *

    		 

    電話番号 *

    デパートメント

    		 

    組纖名 *

    市区町村

    都道府県

    国或いは地域 *

    		      

    必ず会社名を記載ください。個人への返信は行いません。

    備考

    バルクお問い合わせ

    Inquiry Information

    製品名:
    Evolocumab
    製品番号:
    HY-P9930
    数量:
    MCE 日本正規代理店:

    カスタマーレビュー

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    製品名

    		  

    Lot #

    お名前 *

    		 

    メールアドレス *

    電話番号 *

    		 

    部門 *

    組纖名 *

    		 

    国或いは地域 *

    備考

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.